Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBITDA: 2020-2024

Historic EBITDA for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to -$140.1 million.

  • Arcutis Biotherapeutics' EBITDA rose 118.14% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.9 million, marking a year-over-year increase of 76.94%. This contributed to the annual value of -$140.1 million for FY2024, which is 46.35% up from last year.
  • As of FY2024, Arcutis Biotherapeutics' EBITDA stood at -$140.1 million, which was up 46.35% from -$261.1 million recorded in FY2023.
  • Over the past 5 years, Arcutis Biotherapeutics' EBITDA peaked at -$135.7 million during FY2020, and registered a low of -$312.3 million during FY2022.
  • Moreover, its 3-year median value for EBITDA was -$261.1 million (2023), whereas its average is -$237.8 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' EBITDA crashed by 52.28% in 2021, and later soared by 46.35% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' EBITDA (Yearly) stood at -$135.7 million in 2020, then crashed by 52.28% to -$206.6 million in 2021, then plummeted by 51.15% to -$312.3 million in 2022, then rose by 16.41% to -$261.1 million in 2023, then surged by 46.35% to -$140.1 million in 2024.